SpringWorks Therapeutics
CT - Stamford
BiotechnologyFocus: Small Molecules
SpringWorks Therapeutics is a life sciences company focused on Small Molecules.
Oncology
Open Jobs
9
Products & Portfolio (3)
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT05028166Individual Patient Compassionate Use of Mirdametinib
N/ANirogacestat
Desmoid TumorClinical Trials (1)
NCT05041036Individual Patient Compassionate Use of Nirogacestat
N/APF-03084014
NeoplasmClinical Trials (1)
NCT02955446Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies
N/AMirdametinib
HealthyClinical Trials (1)
NCT06997276Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
Phase 1Nirogacestat
HealthyClinical Trials (1)
NCT07171619Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
Phase 1Lifirafenib
Solid Tumor, AdultClinical Trials (1)
NCT03905148Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
Phase 1Mirdametinib
HealthyClinical Trials (1)
NCT07279233To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants
Phase 1Nirogacestat
HealthyClinical Trials (1)
NCT07259330To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants
Phase 1SW-682
Advanced Solid TumorClinical Trials (1)
NCT06251310SW-682 in Advanced Solid Tumors
Phase 1Mirdametinib
NF1Clinical Trials (1)
NCT06159166Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
Phase 1/2Mirdametinib
Well Differentiated LiposarcomaClinical Trials (1)
NCT06843967A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Phase 1/2Mirdametinib
Low-Grade GliomaClinical Trials (1)
NCT04923126SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
Phase 1/2Mirdametinib
Advanced Solid TumorClinical Trials (1)
NCT05580770Mirdametinib + BGB-3245 in Advanced Solid Tumors
Phase 1/2Nirogacestat
Desmoid TumorClinical Trials (1)
NCT05949099Study of Cryoablation and Nirogacestat for Desmoid Tumor
Phase 2Mirdametinib
Plexiform NeurofibromaClinical Trials (1)
NCT03962543MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Phase 2Nirogacestat oral tablet
Desmoid TumorClinical Trials (1)
NCT07170644A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Phase 2Biospecimen Collection
Desmoid FibromatosisClinical Trials (1)
NCT04195399A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Phase 2Nirogacestat
TumorClinical Trials (1)
NCT05879146Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
Phase 2Nirogacestat
Ovarian Granulosa-Stromal TumorClinical Trials (1)
NCT05348356Nirogacestat in Ovarian Granulosa Cell Tumors
Phase 2Nirogacestat oral tablet
Desmoid TumorClinical Trials (1)
NCT03785964Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Phase 3Nirogacestat
Desmoid TumorClinical Trials (1)
NCT07176689Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Phase 4Open Jobs (9)
Territory Business Manager - Kansas City
Remote
Commercial1w ago
$185K - $210K/yr
Regional Business Director – South Central Region (Sarcoma)
Remote
Commercial3w ago
$220K - $255K/yr
Regional Business Director – MidAtlantic Region (Sarcoma)
Remote
Commercial3w ago
$220K - $255K/yr
Regional Business Director – Southeast Region (Sarcoma)
Remote
Commercial3w ago
$220K - $255K/yr
Territory Business Manager - CT/RI
Remote
Commercial1mo ago
$185K - $210K/yr
Territory Business Manager - Phoenix
Remote
Commercial2mo ago
$185K - $210K/yr
Senior Medical Science Liaison – South Central Region
Remote
Medical Affairs2mo ago
$168K - $220K/yr
Director, US Rare Tumor Patient Marketing, Desmoid Tumor (DT)
/ Boston, MA (United States) (Hybrid)
Commercial2mo ago
$165K - $230K/yr
Not Seeing The Job You're Looking For?
Regulatory Affairs
4mo ago
Interview Prep Quick Facts
Portfolio: 3 approved products, 21 clinical trials
Top TAs: Oncology, Gastroenterology
Open Roles: 9 active jobs
Portfolio Health
Growth3 (100%)
3 total products
Hiring Trend
Stable
9
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles